|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 226.08 USD | -1.15% |
|
-0.71% | +27.23% |
| Capitalization | 400B 343B 322B 300B 554B 35,961B 603B 3,764B 1,453B 16,984B 1,500B 1,468B 62,100B | P/E ratio 2025 * |
52.8x | P/E ratio 2026 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise value | 456B 392B 367B 342B 632B 41,003B 687B 4,291B 1,657B 19,365B 1,710B 1,673B 70,807B | EV / Sales 2025 * |
7.48x | EV / Sales 2026 * | 6.7x |
| Free-Float |
96.39% | Yield 2025 * |
2.89% | Yield 2026 * | 3% |
Last Transcript: AbbVie Inc.
| 1 day | -1.15% | ||
| 1 week | -0.71% | ||
| Current month | -0.71% | ||
| 1 month | +4.29% | ||
| 3 months | +6.36% | ||
| 6 months | +20.60% | ||
| Current year | +27.23% |
| 1 week | 223.11 |  | 230.94 |
| 1 month | 216.15 | | 239.29 |
| Current year | 164.39 | | 244.81 |
| 1 year | 164.39 | | 244.81 |
| 3 years | 130.96 | | 244.81 |
| 5 years | 101.55 | | 244.81 |
| 10 years | 50.71 | | 244.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 23/06/2022 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2003 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 73 | 01/01/2013 |
Edward Rapp
BRD | Director/Board Member | 67 | 01/01/2013 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.12% | 6 M€ | 0.00% | - |
| 6.85% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| -1.14% | -3.67% | +29.80% | +37.78% | 150B | |
| Average | -0.30% | -2.37% | +14.01% | +28.34% | 344.69B | |
| Weighted average by Cap. | -0.13% | -2.83% | +18.15% | +55.19% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 60.93B 52.37B 49.06B 45.73B 84.46B 5,483B 91.87B 574B 222B 2,590B 229B 224B 9,469B | 66.62B 57.27B 53.65B 50B 92.35B 5,996B 100B 627B 242B 2,832B 250B 245B 10,354B |
| Net income | 9.1B 7.82B 7.33B 6.83B 12.61B 819B 13.72B 85.7B 33.09B 387B 34.15B 33.42B 1,414B | 17.43B 14.98B 14.03B 13.08B 24.16B 1,569B 26.28B 164B 63.38B 741B 65.41B 64.02B 2,709B |
| Net Debt | 56.02B 48.16B 45.11B 42.05B 77.66B 5,042B 84.48B 528B 204B 2,381B 210B 206B 8,707B | 46.47B 39.95B 37.42B 34.88B 64.42B 4,182B 70.07B 438B 169B 1,975B 174B 171B 7,222B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 226.08 $ | -1.15% | 3,985,199 |
| 04/12/25 | 228.71 $ | -0.66% | 3,733,100 |
| 03/12/25 | 230.24 $ | +2.62% | 4,873,263 |
| 02/12/25 | 224.37 $ | -0.33% | 5,096,922 |
| 01/12/25 | 225.11 $ | -1.14% | 5,208,509 |
Delayed Quote Nyse, December 06, 2025 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition